logo
Ontario health units say measles vaccine registry missing ‘real-time data' on vaccination rates

Ontario health units say measles vaccine registry missing ‘real-time data' on vaccination rates

Under fire for a growing measles outbreak linked to the
death of a newborn
last week, Health Minister Sylvia Jones is calling on people who are vaccine-resistant to get over it.
But public health units in areas hit hard by the highly infectious disease said it's impossible to tell if that's happening because short-term data on measles shots is not immediately available in Ontario's public health system.
'This is a vaccine that has literally existed in the province of Ontario for five decades and when you have two shots you are almost 100 per cent protected. Think about that,'
Jones
said Tuesday.
'All of us are deeply concerned when we hear of individuals who, for any number of reasons, have chosen not to get vaccinated, some because of allergies, some because of religious and other reasons. It impacts us,' she added.
'This is an opportunity for all of us to understand that our actions have an impact on other people.'
The infant who died was born prematurely and was infected in utero through a mother who had not been vaccinated. The newborn was also dealing with other serious health complications.
There were renewed calls for Premier Doug Ford's government to step up efforts to fight measles and encourage shots, after Ontario's Chief Medical Officer, Dr. Kieran Moore on Thursday, revealed the fatality last Thursday.
However, for now, health units can't tell if the infant's death has spurred more interest in shots, which cannot be taken during pregnancy.
'We do not have the ability to pull real-time data on vaccination uptake over a short window like this, unfortunately,' Southwestern Public Health, where the infant's death occurred, said in a statement to the Star.
The health unit is based in St. Thomas to serve Elgin and Oxford counties.
'The majority of vaccination uptake remains at the primary care level, and without a provincial vaccine registry with real-time data, there is no system currently available that can provide this information,' the statement added.
Chatham-Kent Public Health said it is also in the dark.
'At present, we do not have data available to assess any shifts in public sentiment regarding the measles vaccine,' said spokesperson Jacquie Cartwright.
With the province acknowledging last week there have been six cases of congenital infection in the more than 2,000 cases reported in the province since last October, New Democrat MPP Robin Lennox (Hamilton Centre) said Tuesday the province needs a vaccine registry 'that would help us know who is most vulnerable and where to direct our resources.'
The rising infection level shows the government's approach of telling people to see their family doctor or reach out to their local public health unit is not working, Lennox, a family physician, told the Star's Kristin Rushowy last week.
'Obviously, something has broken down, because the advice has been the same for many, many years and this is the only time where we've seen this kind of an outbreak in literally 30 years.'
Public health units have held pop-up clinics near schools and churches since the outbreak began. Many of the current cases can be
traced to a Mennonite wedding in New Brunswick last fall.
Measles had been considered eradicated in Ontario for two decades.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Premature baby dies with measles
Premature baby dies with measles

Hamilton Spectator

time2 hours ago

  • Hamilton Spectator

Premature baby dies with measles

As measles cases across Elgin County and North America continue to rise, a southwestern Ontario infant infected by its unimmunized mother was identified June 5 as Canada's first death related to a measles outbreak that took hold of the nation on Oct. 30, 2024. 'It is with deep sadness that I confirm that an infant, born prematurely and infected with measles, has tragically passed away in southwestern Ontario,' Dr. Kieran Moore, Ontario's Chief Medical Officer of Health said in a statement. Dr. Moore said the infant contracted the virus before birth from the unimmunized mother. While measles may have been a contributing factor in both the premature birth and death, Dr. Moore said that the infant also faced other serious medical complications unrelated to the virus. 'Anyone who is unvaccinated is at risk and I urge everyone, but especially those who may become pregnant, to ensure they have received two doses of the MMR (measles, mumps, and rubella) vaccine, which will protect both a parent and baby,' added Dr. Moore. 'This vaccine has been safely used for over 50 years and is highly effective.' Dr. Ninh Tran, Southwestern Public Health's Medical Officer of Health added: 'This event underscores the seriousness of measles in pregnant individuals, as it can cause low birth weight for the baby, preterm birth, and miscarriage. 'Measles can also cause pneumonia, brain swelling, and death, with infants and immunocompromised individuals especially vulnerable to these risks,' Dr. Tran said in a separate statement. 'The safest and most effective way to protect yourself from measles is through immunization.' The United States has reported 1,088 cases this year, as of June 1, according to a Reuters report. Two children have died in the Texas outbreak. The Government of Canada's latest report shows there are 2,755 measles cases in nine jurisdictions, as of May 24, 2025. That's an increase of 244 measles cases since the previous report. As of June 3, 2025, Ontario has reported a total of 2,009 measles cases in 19 public health units, an increase of 121 cases since the previous week. The weekly provincial report indicates 74.9 percent of measles case in Ontario were infants, children and adolescents, while 24.5 percent were adults. More than 96 percent of all infant, child and adolescent outbreak cases were unimmunized, while 67.3 of adults were unimmunized. A total of 1.9 percent of all cases were pregnant women, with 74.4 percent unimmunized. Six cases of congenital measles, infants diagnosed in the first 10 days of life, have been identified since the Ontario outbreak began on October 30, 2024. SWPH reported 727 cases in the region from Oct 30, 2024 to June 5, 2025, 10 more measles cases since May 29, 2025. More than 74 percent of cases are 18 years old or younger. Nearly 89 percent of cases were unimmunized people. According to the World Health Organization (WHO), before widespread measles vaccinations were available in 1963, major epidemics occurred about every two-to-three years, causing an estimated 2.6 million deaths each year. An estimated 107,500 people died from measles in 2023. Accelerated immunization activities prevented an estimated 60 million deaths from 2000 to 2023, according to WHO. Vaccinations decreased estimated measles deaths from 800,062 in 2000 to 107,500 in 2022. Error! Sorry, there was an error processing your request. There was a problem with the recaptcha. Please try again. You may unsubscribe at any time. By signing up, you agree to our terms of use and privacy policy . This site is protected by reCAPTCHA and the Google privacy policy and terms of service apply. Want more of the latest from us? Sign up for more at our newsletter page .

Starton Therapeutics Announces Phase 2a Clinical Trial for Continuous Low-Dose Lenalidomide (STAR-LLD) in Multiple Myeloma Open for Enrollment
Starton Therapeutics Announces Phase 2a Clinical Trial for Continuous Low-Dose Lenalidomide (STAR-LLD) in Multiple Myeloma Open for Enrollment

Yahoo

time3 hours ago

  • Yahoo

Starton Therapeutics Announces Phase 2a Clinical Trial for Continuous Low-Dose Lenalidomide (STAR-LLD) in Multiple Myeloma Open for Enrollment

Gabrail Cancer & Research Center activated and open to screen patients, with Nash Gabrail, MD as lead investigator Second site, Regional Medical Oncology Center, also activated Recent Phase 1b clinical study results concluded continuous low dose lenalidomide provides meaningful efficacy and improved tolerability with no grade >3 drug-related hematologic toxicity PARAMUS, N.J., June 12, 2025 (GLOBE NEWSWIRE) -- Starton Therapeutics Inc. ('Starton'), a clinical-stage biotechnology company transforming standard-of-care therapies with proprietary continuous delivery technologies, announced today Gabrail Cancer Center (GCC) in Canton, Ohio is now activated and open for enrolling patients in its Phase 2a clinical trial evaluating their continuous low-dose lenalidomide, STAR-LLD, for the treatment of multiple myeloma (MM). Dr. Nash Gabrail, medical oncologist and founder of the Center, is the study's lead investigator. Regional Medical Oncology Center, located in Wilson, NC, has also opened as the trial's second active clinical site. 'We are excited to announce this major milestone in our mission to bring breakthrough therapies to patients. This marks the next phase of development for our lead candidate, STAR-LLD, and represents a significant step forward for the entire team," stated Pedro Lichtinger, Chairman and Chief Executive Officer of Starton Therapeutics. 'We expect this study to expand on what we observed in our prior Phase 1b study, that continuous low-dose lenalidomide provides meaningful efficacy and improved tolerability,' added Dr. Jamie Oliver, Starton's Chief Medical Officer. 'The expanded cohort and dose escalation will help us determine the most effective dose, with the goal of maintaining acceptable safety and tolerability.' Starton, which recently presented the results of the Phase 1b portion of the study at the 2025 American Association for Cancer Research, will assess the safety and tolerability of low-dose lenalidomide in heavily treated MM patients. Continuous SC infusion (STAR-LLD) in combination with dexamethasone and a protease inhibitor (PI) will be compared to oral lenalidomide (Revlimid®) in combination with dexamethasone and a PI. The study will include at least 24 patients randomized to STAR-LLD and oral lenalidomide (Revlimid®). Up to 45 additional patients may be enrolled to identify the optimal dose for a future registrational study (based on ORR vs dose vs Grade 3-4 toxicity). Starton anticipates opening approximately 10 clinical sites. About STAR-LLD STAR-LLD is a continuous delivery lenalidomide (LLD) in development to expand and replace the standard-of-care for the most common blood cancers, multiple myeloma (MM), and chronic lymphocytic leukemia (CLL). A preclinical proof-of-concept study for subcutaneous STAR-LLD demonstrated that MM tumors caused by human myeloma cells grew 25-fold if untreated, five-fold when treated with daily lenalidomide, and shrank by 80% with STAR-LLD over a single 28-day cycle. The study also showed a 100% overall response rate (ORR) using continuous delivery LLD and 20% of animals in this cohort were tumor-free after 100 days, compared to a 0% ORR in animals treated with a 70% higher dose of lenalidomide given in single daily doses. In addition, a Phase 1b clinical study of six relapsed/refractory MM patients resulted in all patients that received STAR-LLD achieving an objective response (1 CR and 5 PRs); no patients experienced drug-related anemia, neutropenia, leukopenia, or thrombocytopenia greater than grade 2 in up to 12 cycles of therapy. The study concluded that continuous delivery of low dose lenalidomide (STAR-LLD) provides meaningful efficacy and improved tolerability with no grade > 2 drug-related hematologic toxicity. About Starton Therapeutics Starton Therapeutics is a clinical-stage biotechnology platform company focused on transforming standard-of-care therapies with proprietary continuous delivery technology, so people with cancer live better, for longer. Starton's proprietary technology is intended to increase the efficacy of approved drugs, make them more tolerable, and expand their potential use. To learn more, visit Forward Looking Statements All statements other than statements of historical facts included in this press release, including, without limitation, statements regarding our plans and objectives for future operations and expectations about current and future clinical trials, constitute 'forward-looking statements.' Forward-looking statements are subject to numerous conditions and known and unknown risks and uncertainties that could cause our actual results or events to differ materially from those included within the forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements, and except as required by law, Starton undertakes no obligation to disclose any revision to these forward-looking statements whether as a result of new information, future events, or otherwise. Investor Relations Contact Alex StarrManaging Director LifeSci Advisors astarr@ in to access your portfolio

Matteson man who survived prostate cancer spreading the word about early detection
Matteson man who survived prostate cancer spreading the word about early detection

Chicago Tribune

time4 hours ago

  • Chicago Tribune

Matteson man who survived prostate cancer spreading the word about early detection

Andrin 'AJ' Jones got some scary news when he was diagnosed with prostate cancer, but his experience has pushed him to try to make a difference in other men's lives now that he's a survivor. Jones, a 62-year-old retired Air Force veteran, counts himself lucky that his cancer was caught early enough that it had not spread, so that surgically removing his prostate in 2023 left him healthy. So he wants to spread that good fortune to others by spreading his story about how early testing leads to better outcomes. 'My prognosis was excellent because the biopsy showed the cancer was still contained within the walls of my prostate,' said Jones, who lives in Matteson with his wife, also an Air Force veteran. 'Because of early detection, it had not yet metastasized, the risk level was low to intermediate. I was so thankful for that.' His journey with prostate cancer started in May 2022, when Dr. Lance Wallace, his internist at Specialty Physicians of Illinois, LLC, ordered a full panel of screening labs, including a prostate specific antigen test. That test revealed he had an elevated level of that antigen in his blood. After Wallace saw the test result, he waited a few months to recheck the labs, but they were higher. So he referred Andrin to Dr. James Siegert, a urologist and urological surgeon, also with Specialty Physicians of Illinois, LLC, and practicing with Franciscan Health Olympia Fields, who redid the labs to watch for a trend in elevations. He did the biopsy several months later and found Stage 2 adenocarcinoma. 'Of course I was alarmed at the diagnosis, but at the same time, it was a good reality check to encourage men to not ignore any symptoms,' said Andrin. Andrin said he was given a choice of radiation or surgery and opted for the latter. Siegert said prostate cancer screening was generally recommended for 50- to 60-year-old men at average risk, but for those at increased risk, such as African-American men or those with a family history, the age recommendation drops to 40 to 45. The screening is not usually recommended for men 70 or older. 'Prostate cancer screening is important because it can help detect cancer early, when it's most treatable and potentially curable,' Siegert said. 'Early detection through a PSA blood test may allow patients to avoid more serious complications down the line and preserve their quality of life.' Wallace, Jones' primary care physician, also encouraged early screening. 'Like anything, the earlier you catch it, the less treatment will be involved in treating the cancer, and the chance for success is greater,' Wallace said. Jones said there were a few things that helped him get through the experience, including building a strong relationship with both physicians. 'I'm a person of faith, I trusted God with the situation,' he said. 'I started going for walks in the morning to mentally process things that were going on. 'Along with my wife, family, and church family, that helped me have a good mental perspective,' he said. No matter how difficult the ordeal was he often reminds himself, 'I had cancer — today I don't.' 'Being honest and open with other men about prostate screening' has provided a source of strength for Jones, he said. He still does that on regular walks with his comrades. He also teaches classes on the Bible and is an avid hiker and biker. Siegert said he was struck by Jones' resilience. 'Of the hundreds of men I diagnose and treat for prostate cancer per year, Mr. Jones was unique as throughout his treatment, he maintained a remarkably positive attitude, approaching each step with resilience and hope,' said Siegert. 'Inspired by his experience, he has become a passionate advocate for prostate cancer awareness and early screening, particularly within the African-American and veteran communities, using his voice to encourage others to take charge of their health.'

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store